→
Bristol-Myers Squibb Co's current price of $59.11 represents a solid entry point, especially considering its impressive EPS growth of 26.27% year-over-year, which indicates robust profitability. With a market cap of $119.54B and a dividend yield of 4.30%, the company's strong fundamentals and positive analyst sentiment, where 6 analysts rate it as a 'Strong Buy', reinforce a bullish outlook.
Investors should consider accumulating BMY shares, taking advantage of its solid fundamentals and attractive dividend yield.
Bristol-Myers Squibb's recent earnings performance has been impressive, consistently beating estimates, with Q1 2026 EPS at $1.58 compared to the expected $1.43. Furthermore, the company's focus on innovation, particularly in Alzheimer's research, could unlock significant future revenue streams.
Despite upbeat earnings, revenue growth of only 1.78% year-over-year suggests potential stagnation in sales, which poses a risk to future earnings. Additionally, with a P/B ratio of 6.17, the stock may be overvalued compared to its book value, potentially limiting upside in a downturn.
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes every holding, and delivers actionable intelligence weekly.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Helm's AI rates BMY as Bullish. Investors should consider accumulating BMY shares, taking advantage of its solid fundamentals and attractive dividend yield.
Despite upbeat earnings, revenue growth of only 1.78% year-over-year suggests potential stagnation in sales, which poses a risk to future earnings. Additionally, with a P/B ratio of 6.17, the stock may be overvalued compared to its book value, potentially limiting upside in a downturn.
Bristol-Myers Squibb's recent earnings performance has been impressive, consistently beating estimates, with Q1 2026 EPS at $1.58 compared to the expected $1.43. Furthermore, the company's focus on innovation, particularly in Alzheimer's research, could unlock significant future revenue streams.
Bristol-Myers Squibb Co's current price of $59.11 represents a solid entry point, especially considering its impressive EPS growth of 26.27% year-over-year, which indicates robust profitability. With a market cap of $119.54B and a dividend yield of 4.30%, the company's strong fundamentals and positive analyst sentiment, where 6 analysts rate it as a 'Strong Buy', reinforce a bullish outlook.
Bristol-Myers Squibb Co's current price of $59.11 represents a solid entry point, especially considering its impressive EPS growth of 26.27% year-over-year, which indicates robust profitability. With a market cap of $119.54B and a dividend yield of 4.30%, the company's strong fundamentals and positive analyst sentiment, where 6 analysts rate it as a 'Strong Buy', reinforce a bullish outlook. Our overall verdict is Bullish.
Helm Terminal offers free AI-powered stock analysis for BMY at helmterminal.dev/analyze/BMY, updated continuously during US market hours. No signup required.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.